|
|
5-day change | 1st Jan Change | ||
|
690.77 USD |
+2.54% | +4.00% | +20.99% | |
April 02, 2025 at 11:56 am EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
McKesson Likely to See Strong Growth Amid Favorable Pharma Sector, Morgan Stanley Says |
11:56am |
MT |
|
Leerink Partners Adjusts PT on McKesson to $745 From $732, Maintains Outperform Rating |
10:46am |
MT |
|
McKesson Closes $850 Million Acquisition of Controlling Stake in Prism Vision |
09:32am |
MT |
|
Morgan Stanley Raises Price Target on McKesson to $745 From $642, Keeps Overweight Rating |
06:57am |
MT |
|
Deutsche Bank Raises Price Target on McKesson to $700 From $663 |
Mar. 26 |
MT |
|
Wells Fargo Adjusts Price Target on McKesson to $691 From $641, Maintains Equalweight Rating |
Mar. 14 |
MT |
|
Mckesson Insider Sold Shares Worth $5,684,059, According to a Recent SEC Filing |
Mar. 07 |
MT |
|
Leerink Partners Adjusts Price Target on McKesson to $732 From $690, Keeps Outperform Rating |
Mar. 07 |
MT |
|
Lumata Health Secures $23 Million Series B Funding Round Co-Led By Lrvhealth, Mckesson Ventures, Cencora Ventures |
Mar. 05 |
RE |
|
McKesson Corporation Presents at TD Cowen 45th Annual Healthcare Conference, Mar-04-2025 09:50 AM |
Mar. 04 |
|
|
Mckesson Insider Sold Shares Worth $5,591,664, According to a Recent SEC Filing |
Mar. 03 |
MT |
|
Mckesson Insider Sold Shares Worth $5,358,588, According to a Recent SEC Filing |
Feb. 24 |
MT |
|
Mckesson Insider Sold Shares Worth $5,382,514, According to a Recent SEC Filing |
Feb. 18 |
MT |
|
Baird Adjusts McKesson Price Target to $730 From $729, Maintains Outperform Rating |
Feb. 18 |
MT |
|
McKesson, AmerisourceBergen’s Joint Motion to Dismiss Antitrust Case Granted by Pennsylvania Judge |
Feb. 06 |
MT |
|
Leerink Partners Adjusts Price Target on McKesson to $690 From $667 |
Feb. 06 |
MT |
|
Evercore ISI Adjusts Price Target on McKesson to $675 From $650 |
Feb. 06 |
MT |
|
Baird Adjusts Price Target on McKesson to $729 From $693 |
Feb. 06 |
MT |
|
Deutsche Bank Adjusts McKesson Price Target to $663 From $628, Maintains Buy Rating |
Feb. 06 |
MT |
|
McKesson misses third-quarter revenue estimates |
Feb. 05 |
RE |
|
McKesson Fiscal Q3 Adjusted EPS, Revenue Increase; 2025 Outlook Updated — Shares Down After Hours |
Feb. 05 |
MT |
|
McKesson Corporation, Q3 2025 Earnings Call, Feb 05, 2025 |
Feb. 05 |
|
|
McKesson Narrows FY 2025 EPS View to $32.55-$32.95, vs Prior Guidance of $32.40-$33 and FactSet Analyst Consensus of $32.68/Share |
Feb. 05 |
MT |
|
McKesson Reports Q3 EPS of $8.03 on Revenue of $95.3 Billion, vs FactSet Analyst Consensus of $8.00/Share on Revenue of $96 Billion |
Feb. 05 |
MT |
|
Equities Mixed After Macro Data, Corporate Earnings |
Feb. 05 |
MT |
MCK: Dynamic Chart
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
– distribution of pharmaceutical products (90.2%);
– distribution of medical and surgical products (3.4%);
– other (1.8%): primarily technology services and software sales.
The remaining net sales (4.6%) are from international activities.
More about the company
Buy
Last Close Price
673.69USD
Average target price
679.38USD
Spread / Average Target
+0.84%
Consensus
